Loading market dashboard
Kuros Biosciences AG
CSBTFHealthcareOTCCH
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% to USD 43.4 million (Q1 2025: USD 28.8 million) Direct MagnetOs™ product sales increased by 51% to USD 42.9 million (Q1 2025: USD 28.4 million) Group EBITDA reached USD 2.9 million (Q1 2025: EBITDA of USD 2.0 million) Group adjusted EBITDA* amounted to USD 5.7 million, equaling a margin of 13.1% (Q1 2025: USD 3.3 million at 11.6%) Cash and cash equivalents totaled USD 15.7 million, compared to USD 19.8 million as of December 31, 2025, reflecting investments in the diversification and optimization of production capacity to support long-term growth Clinical & Operational Highlights Kuros continued to achieve significant progress in its extremities segment along with strong adoption of MagnetOs MIS in minimally invasive surgeries, reflecting broader adoption across various specialties in multiple care settings A retrospective study led by Dr. Mark Eskander was published in Spine Open and reported an overall fusion rate of 87% for MagnetOs Easypack Putty in a high-risk patient population assessing 70 posterior lumbar fusion patients, with an 84.2% fusion rate in patients assessed at
Kuros Biosciences AG (CSBTF) Q4 2025 Earnings Call Transcript
